Rieke Alten1, Xavier Mariette2, Hanns-Martin Lorenz3, Hubert Nüßlein4, Mauro Galeazzi5, Federico Navarro6, Melanie Chartier7, Julia Heitzmann8, Coralie Poncet9, Christiane Rauch10, Manuela Le Bars11,12. 1. Department of Internal Medicine, Rheumatology, Clinical Immunology, and Osteology, Schlosspark-Klinik University Medicine Berlin, Heubnerweg 2, 14059, Berlin, Germany. rieke.alten@schlosspark-klinik.de. 2. Department of Rheumatology, Université Paris-Sud, Paris, France. 3. Department of Rheumatology, University Hospital, Heidelberg, Germany. 4. Department of Internal Medicine and Rheumatology, University of Erlangen-Nuremberg, Nuremberg, Germany. 5. Department of Medical Sciences, Surgery, and Neuroscience, University of Siena, Siena, Italy. 6. Department of Rheumatology, Hospital Universitario Virgen Macarena, Seville, Spain. 7. Marketed Product Late Stage Operation Department, Bristol-Myers Squibb, Rueil-Malmaison, France. 8. Excelya, Boulogne-Billancourt, France. 9. Docs International, Issy-les-Moulineaux, France. 10. Department of Immunoscience, Bristol-Myers Squibb, Munich, Germany. 11. Speciality Development Immunology, Bristol-Myers Squibb, Rueil-Malmaison, France. 12. Janssen-Cilag European Medical Affairs Immunology-Gastroenterology, 92787, Issy-les-Moulineaux, France.
Abstract
OBJECTIVES: Evaluate abatacept retention over 2 years in the AbataCepT In rOutiNe clinical practice (ACTION) study. METHOD: ACTION was an international, observational study of patients with moderate-to-severe rheumatoid arthritis (RA) who initiated intravenous abatacept. Crude abatacept retention rates over 2 years were estimated using Kaplan-Meier analyses in biologic-naive and -failure patients. Clinically relevant risk factors and significant prognostic factors for retention were evaluated using a Cox proportional hazards multivariable model. RESULTS: Overall, 2350/2364 enrolled patients were evaluable; 673 (28.6%) were biologic naive and 1677 (71.4%) had prior biologic failure (1 biologic, 728/1677 [43.4%]; ≥ 2 biologics, 949/1677 [56.6%]). Abatacept retention rate (95% confidence interval [CI]) at 2 years was 47.9% (45.7, 50.0): 54.5% (50.4, 58.3) for biologic-naive vs 45.2% (42.7, 47.7) for biologic-failure patients (log-rank P < 0.001). For patients with 1 and ≥ 2 prior biologic failures, respectively, retention rates (95% CI) were 50.2% (46.3, 53.9) vs 41.3% (38.0, 44.6; log-rank P < 0.001). Main reasons for discontinuation (biologic-naive vs biologic-failure, respectively) were lack of efficacy (61.4 vs 67.7%) and safety (21.3 vs 21.2%). Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) double positivity versus negativity were predictive of higher retention in both biologic-naive (hazard ratio [HR] [95% CI] 0.71 [0.53, 0.96]; P = 0.019) and biologic-failure patients (HR [95% CI] 0.76 [0.62, 0.94]; P = 0.035). CONCLUSIONS: Abatacept initiation as earlier vs later line of therapy in RA may achieve higher 2-year retention rates. RF and anti-CCP seropositivity could predict increased abatacept retention, irrespective of treatment line. TRIAL REGISTRATION: NCT02109666.
OBJECTIVES: Evaluate abatacept retention over 2 years in the AbataCepT In rOutiNe clinical practice (ACTION) study. METHOD: ACTION was an international, observational study of patients with moderate-to-severe rheumatoid arthritis (RA) who initiated intravenous abatacept. Crude abatacept retention rates over 2 years were estimated using Kaplan-Meier analyses in biologic-naive and -failure patients. Clinically relevant risk factors and significant prognostic factors for retention were evaluated using a Cox proportional hazards multivariable model. RESULTS: Overall, 2350/2364 enrolled patients were evaluable; 673 (28.6%) were biologic naive and 1677 (71.4%) had prior biologic failure (1 biologic, 728/1677 [43.4%]; ≥ 2 biologics, 949/1677 [56.6%]). Abatacept retention rate (95% confidence interval [CI]) at 2 years was 47.9% (45.7, 50.0): 54.5% (50.4, 58.3) for biologic-naive vs 45.2% (42.7, 47.7) for biologic-failurepatients (log-rank P < 0.001). For patients with 1 and ≥ 2 prior biologic failures, respectively, retention rates (95% CI) were 50.2% (46.3, 53.9) vs 41.3% (38.0, 44.6; log-rank P < 0.001). Main reasons for discontinuation (biologic-naive vs biologic-failure, respectively) were lack of efficacy (61.4 vs 67.7%) and safety (21.3 vs 21.2%). Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) double positivity versus negativity were predictive of higher retention in both biologic-naive (hazard ratio [HR] [95% CI] 0.71 [0.53, 0.96]; P = 0.019) and biologic-failurepatients (HR [95% CI] 0.76 [0.62, 0.94]; P = 0.035). CONCLUSIONS: Abatacept initiation as earlier vs later line of therapy in RA may achieve higher 2-year retention rates. RF and anti-CCP seropositivity could predict increased abatacept retention, irrespective of treatment line. TRIAL REGISTRATION: NCT02109666.
Authors: Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink Journal: Semin Arthritis Rheum Date: 2010-08 Impact factor: 5.532
Authors: David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers Journal: Ann Rheum Dis Date: 2011-03 Impact factor: 19.103
Authors: Joel M Kremer; Harry K Genant; Larry W Moreland; Anthony S Russell; Paul Emery; Carlos Abud-Mendoza; Jacek Szechiński; Tracy Li; Julie Teng; Jean-Claude Becker; René Westhovens Journal: Arthritis Rheum Date: 2008-04
Authors: M C Genovese; M Schiff; M Luggen; J-C Becker; R Aranda; J Teng; T Li; N Schmidely; M Le Bars; M Dougados Journal: Ann Rheum Dis Date: 2007-10-05 Impact factor: 19.103
Authors: Rene Westhovens; Joel M Kremer; Paul Emery; Anthony S Russell; Rieke Alten; Emilie Barré; Maxime Dougados Journal: Clin Exp Rheumatol Date: 2014-07-08 Impact factor: 4.473
Authors: A Finckh; D Neto; F Iannone; E Loza; E Lie; P van Riel; M L Hetland; K Pavelka; J E Gottenberg; H Canhão; X Mariette; C Turesson Journal: RMD Open Date: 2015-04-30
Authors: Valquiria G Dinis; Vilma T Viana; Elaine P Leon; Clóvis A Silva; Carla G Saad; Julio C Moraes; Eloisa S Bonfa; Ana C Medeiros-Ribeiro Journal: Clin Rheumatol Date: 2020-01-11 Impact factor: 2.980
Authors: Rieke Alten; Xavier Mariette; René-Marc Flipo; Roberto Caporali; Maya H Buch; Yusuf Patel; Sara Marsal; Raimon Sanmartí; Michael T Nurmohamed; Hedley Griffiths; Peter Peichl; Bettina Bannert; Melanie Chartier; Sean E Connolly; Karissa Lozenski; Christiane Rauch Journal: Clin Rheumatol Date: 2022-05-10 Impact factor: 3.650
Authors: R Westhovens; S E Connolly; J Margaux; M Vanden Berghe; M Maertens; M Van den Berghe; Y Elbez; M Chartier; F Baeke; S Robert; M Malaise Journal: Rheumatol Int Date: 2020-06-17 Impact factor: 2.631